Loading...
XHKG
1345
Market cap308mUSD
Dec 05, Last price  
2.07HKD
1D
-2.82%
1Q
18.97%
Jan 2017
-26.07%
IPO
-47.59%
Name

Shanghai Pioneer Holding Ltd

Chart & Performance

D1W1MN
XHKG:1345 chart
P/E
14.37
P/S
1.42
EPS
0.13
Div Yield, %
3.48%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
3.07%
Revenues
1.53b
-2.27%
570,647,000717,831,000958,723,0001,272,247,0001,540,398,0001,460,899,0001,790,275,0002,153,935,0001,624,305,0001,315,978,0001,332,037,0001,434,820,0001,556,040,0001,566,673,0001,531,050,000
Net income
152m
+4.05%
70,435,00095,675,000186,369,000238,372,000261,718,000174,302,000237,445,000278,925,00084,597,000104,627,00052,448,000142,633,000235,296,000145,718,000151,618,000
CFO
215m
P
71,205,000-21,777,000120,758,00047,937,000-17,778,000304,690,000342,039,000233,628,000128,667,000280,642,00074,239,000242,064,00093,295,000-118,686,000214,831,000
Dividend
Jun 03, 20250.056 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. It has a portfolio of pharmaceutical products, such as ophthalmology, pain management, cardiovascular, immunology, gynecology, gastroenterology, and other therapeutic areas, as well as medical devices, including ophthalmology, orthopedics, odontology, and wound care products. The company sells its products to hospitals and medical institutions, and pharmacies. It also sells ancillary tools and leases accessories; and sells dental devices. In addition, the company engages in the sale of imported in-licensed prescription products. China Pioneer Pharma Holdings Limited was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. China Pioneer Pharma Holdings Limited is a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
URL
http://www.pioneer-pharma.com/
IPO date
Nov 05, 2013
Employees
361
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT